關鍵數據
1.820今開
1.950最高
667.00成交量
虧損本益比TTM
虧損本益比動
--股利TTM
0.01%換手率
1.810昨收
1.750最低
1.17K成交額
虧損本益比靜
0.54市淨率
0.00%股息率 TTM
-28.93%ROA
3.06552週最高
0.07量比
-13.56M淨利潤
10.87M總股本
-4.6080每股盈餘TTM
0.24Beta
-97.42%ROE
1.75052週最低
9.39%振幅
59.62%毛利率
19.89M總市值
3.12回報/風險
2.79%風險率

即將為您帶來更多新聞,敬請期待。 。 。
Aytu Biopharma Inc評分
0.06與上次評分對比預測8.00
財務診斷7.23
技術分析3.97
公司估值8.74
機構認同度3.00
風險評估4.02
分析師評級
買入評級
9.667目標均價
+400.86%漲幅空間
Aytu Biopharma Inc 最新財報電話會記錄
Aytu BioPharma (AYTU) 2026 財年第四季財報電話會議:EXXUA 成長與 2027 財年展望
Aytu BioPharma 2026 財年第四季營收成長 6% 至 1,610 萬美元,主因 EXXUA 銷售額達到 390 萬美元。管理層並提出了 2027 財年的支出與利潤率目標。
財務指標
貨幣: USD

由於公司未披露,未能獲取相關數據
貨幣: USD

由於公司未披露,未能獲取相關數據
Aytu Biopharma Inc 簡介
Aytu BioPharma, Inc. is a pharmaceutical company focused on commercializing novel therapeutics. The Company's business is focused on its prescription pharmaceutical products sold primarily through third party wholesalers and pharmacies and which primarily consists of two product portfolios. The first consists of two products for the treatment of ADHD: Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets (Adzenys) and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets. The second consists primarily of Karbinal ER (carbinoxamine maleate extended-release oral suspension), an extended-release first-generation antihistamine suspension containing carbinoxamine indicated to treat numerous allergic conditions, and Poly-Vi-Flor and Tri-Vi-Flor, two complementary prescription fluoride-based supplement product lines containing combinations of fluoride and vitamins in various formulations for infants and children with fluoride deficiency.
行業藥品
公司代碼AYTU
員工數量82
國家United States of America
持股情況
| 持股股東 | 佔比 |
|---|
| Nantahala Capital Management, LLC | 10.13% |
|---|
| Stonepine Capital Management, LLC | 7.58% |
|---|
| AWM Investment Company, Inc. | 5.77% |
|---|
| Lytton (Laurence W) | 4.99% |
|---|
| 股東類型 | 佔比 |
|---|
| Investment Advisor/Hedge Fund | 16.18% |
|---|
| Hedge Fund | 16.10% |
|---|
| Individual Investor | 8.98% |
|---|
| Investment Advisor | 3.85% |
|---|
常見問題
Aytu Biopharma Inc(AYTU)的當前股價是多少?
Aytu Biopharma Inc(AYTU)的當前股價是 1.83。
Aytu Biopharma Inc 的股票代碼是什麼?
Aytu Biopharma Inc的股票代碼是AYTU。
Aytu Biopharma Inc股票的52週最高點是多少?
Aytu Biopharma Inc股票的52週最高點是3.06。
Aytu Biopharma Inc股票的52週最低點是多少?
Aytu Biopharma Inc股票的52週最低點是1.75。
Aytu Biopharma Inc的市值是多少?
Aytu Biopharma Inc的市值是19.89M。
現在Aytu Biopharma Inc(AYTU)的股票是買入、持有還是賣出?
根據分析師評級,Aytu Biopharma Inc(AYTU)的總體評級為買入,目標價格為9.67。
Aytu Biopharma Inc(AYTU)股票的每股收益(EPS TTM)是多少
Aytu Biopharma Inc(AYTU)股票的每股收益(EPS TTM)是-4.61。